Vaishali Pharma adjusts allotment consideration based on valuation report

1 min read     Updated on 19 Jun 2026, 02:30 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Vaishali Pharma Ltd will receive ₹2,15,258 from Kesar Pharma Ltd to align preferential allotment consideration with a registered valuer's report. The adjustment addresses a ₹0.10 per share difference on 21,52,575 shares acquired.

powered bylight_fuzz_icon
43362013

*this image is generated using AI for illustrative purposes only.

Vaishali Pharma Ltd will receive ₹2,15,258 in cash from Kesar Pharma Ltd to align the consideration for a preferential allotment with a registered valuer's report. The adjustment addresses a discrepancy of ₹0.10 per share on 21,52,575 equity shares of Kesar Pharma Ltd acquired by the company. This ensures the transaction complies with the valuation determined by the Registered Valuer and applicable regulatory requirements.

The company's members had approved the issuance of up to 61,23,000 equity shares on a preferential basis to Kesar Pharma Ltd through a postal ballot on March 15, 2026. The approval was initially based on acquiring 21,52,575 equity shares of Kesar Pharma Ltd at a value of ₹56.89 per equity share. However, the valuation report later determined the value at ₹56.79 per equity share, creating the differential amount.

The following table outlines the financial details of the adjustment:

Particulars Details
Total shares of Kesar Pharma Ltd acquired 21,52,575
Initial valuation per share (₹) 56.89
Registered Valuer's price per share (₹) 56.79
Difference per share (₹) 0.10
Aggregate differential amount (₹) 2,15,258

The aggregate differential amount of ₹2,15,258, calculated at ₹0.10 per share on the total shares acquired, will be received in cash from Kesar Pharma Ltd. Consequently, the consideration for the transaction stands adjusted to the extent of this amount. This disclosure was made pursuant to an observation received from the National Stock Exchange of India Limited in connection with the company's application for in-principle approval.

Historical Stock Returns for Vaishali Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.04%+5.71%+10.48%-14.33%-38.79%+94.62%

How will this cash adjustment impact Vaishali Pharma's working capital or liquidity position in the upcoming quarter?

Does the resolution of this valuation discrepancy expedite the National Stock Exchange's approval for the preferential allotment?

What strategic benefits does Vaishali Pharma expect to gain from acquiring equity shares in Kesar Pharma Ltd?

Vaishali Pharma seeks nod for director re-appointments, pay revision

2 min read     Updated on 04 Jun 2026, 02:45 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Vaishali Pharma Limited has announced a postal ballot to secure shareholder approval for the re-appointment of Mr. Pratik Vikram Jakhelia as Independent Director, Mr. Atul Arvind Vasani as Managing Director, and Mrs. Jagruti Vasani as Whole-Time Director, along with a remuneration hike for Director cum CFO Mr. Dewansh Ajay Vasani. The e-voting process runs from June 4 to July 3, 2026, with results expected by July 7, 2026. The proposed remuneration for the Managing Director and Whole-Time Director exceeds statutory limits, requiring approval via special resolution.

powered bylight_fuzz_icon
42066911

*this image is generated using AI for illustrative purposes only.

vaishali pharma has initiated a postal ballot process to seek shareholder approval for the re-appointment of three directors and a revision in remuneration for its Director cum Chief Financial Officer. The resolutions, which require special approval, pertain to the re-appointment of Mr. Pratik Vikram Jakhelia as an Independent Director, Mr. Atul Arvind Vasani as Managing Director, and Mrs. Jagruti Vasani as a Whole-Time Director, alongside a remuneration increase for Mr. Dewansh Ajay Vasani.

The Board of Directors, at its meeting held on May 23, 2026, approved the proposals based on the recommendations of the Nomination and Remuneration Committee. The re-appointments are for a term of five years, commencing from May 23, 2026, for the executive directors and from October 1, 2026, for the Independent Director. The remuneration revisions for Mr. Atul Arvind Vasani and Mrs. Jagruti Vasani exceed the limits prescribed under Schedule V of the Companies Act, 2013, necessitating shareholder consent via special resolution.

The company has engaged Central Depository Services (India) Limited (CDSL) to facilitate the remote e-voting process. The voting period begins at 10:00 A.M. IST on Thursday, June 4, 2026, and ends at 5:00 P.M. IST on Friday, July 3, 2026. Shareholders whose names appear in the Register of Members or Register of Beneficial Owners as on the cut-off date of May 22, 2026, are eligible to vote.

Remuneration Details

The postal ballot notice outlines specific remuneration structures for the directors seeking re-appointment and the proposed revision for the CFO. The remuneration for Mr. Atul Arvind Vasani is proposed to increase from ₹84 Lakhs per annum to ₹96 Lakhs per annum, while Mrs. Jagruti Vasani’s remuneration is set to rise from ₹24 Lakhs per annum to ₹30 Lakhs per annum.

Director Proposed Remuneration Previous Remuneration Tenure
Mr. Atul Arvind Vasani (Managing Director) ₹96,00,000 per annum ₹84,00,000 per annum 5 years (May 23, 2026 to May 22, 2031)
Mrs. Jagruti Vasani (Whole-Time Director) ₹30,00,000 per annum ₹24,00,000 per annum 5 years (May 23, 2026 to May 22, 2031)
Mr. Dewansh Ajay Vasani (Director cum CFO) ₹24,00,000 per annum ₹18,00,000 per annum Effective from May 23, 2026

The re-appointment of Mr. Pratik Vikram Jakhelia as an Independent Director is for a second term of five years, ending on September 30, 2031. He is not liable to retire by rotation and will be entitled to sitting fees and remuneration for attending Board and Committee meetings as approved by the Board.

Voting and Results

HD and Associates, Practicing Company Secretary, has been appointed as the Scrutinizer to ensure the conduct of the postal ballot is fair and transparent. The results of the postal ballot will be announced on or before 5:00 P.M. IST on Tuesday, July 7, 2026, and will be submitted to the stock exchanges within two working days of the conclusion of the e-voting period.

In compliance with Ministry of Corporate Affairs circulars, the notice is being sent only through electronic mode to members whose email addresses are registered with the company or depositories. The company has stated that hard copies of the postal ballot notice and forms will not be dispatched to members.

Historical Stock Returns for Vaishali Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.04%+5.71%+10.48%-14.33%-38.79%+94.62%

How will the increased remuneration packages impact the company's operational profitability and shareholder returns over the next five years?

What strategic growth initiatives does the board plan to prioritize during the new five-year tenure of the re-appointed executive directors?

Could the significant remuneration hikes, exceeding Schedule V limits, trigger any dissent from institutional investors during the e-voting process?

More News on Vaishali Pharma

1 Year Returns:-38.79%